Furthermore, Cerdulatinib significantly inhibited the viability of CD19+ cells isolated from 60 primary chronic lymphocytic leukemia (CLL) patient samples at clinically attainable concentrations. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.